Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Hafez

Neurological Surgery Saint Louis, MO Medical Doctor

NPI 1134534621 CMS profile 879449

12634 Olive Blvd, Dept Neurological Surgery, Saint Louis, MO 63141

Open in the dashboard

General payments

$272,598

323 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$599

1 holding reported · through program year 2025

Through program year 2025, Daniel Hafez of Saint Louis, MO is reported in the CMS Open Payments database as having received $272,598 across 323 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $599 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $161,641 167
2024 General $30,613 65
2023 General $12,779 41
2022 General $6,479 40
2021 General $60,781 8
2020 General $174 1
2019 General $132 1
2025 Ownership $599 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Hafez
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Daniel Hafez were reported at $161,641. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Daniel Hafez Neurological Surgery median Middle half National median
2019 $132 $582 $138–$3,006 $163
2020 $174 $294 $76–$2,174 $114
2021 $60,781 $387 $105–$2,432 $132
2022 $6,479 $542 $139–$2,989 $149
2023 $12,779 $534 $145–$2,697 $160
2024 $30,613 $574 $155–$3,046 $164
2025 $161,641 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $81,998 134 payments
  2. Arthrex, Inc. $62,591 39 payments
  3. NuVasive, Inc. $60,536 5 payments
  4. elliquence, LLC $33,233 17 payments
  5. DePuy Synthes Products, Inc. $13,069 13 payments
  6. Spineology Inc. $9,083 19 payments
  7. Alphatec Spine, Inc $4,007 21 payments
  8. Medtronic, Inc. $3,691 25 payments
  9. DePuy Synthes Sales Inc. $730 11 payments
  10. Stryker Corporation $623 7 payments
  11. Other $3,037 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $102,375 34 payments
  2. Grant $60,000 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,450 8 payments
  4. Travel and Lodging $39,995 116 payments
  5. Food and Beverage $13,524 163 payments
  6. Entertainment $255 1 payment
Products named General payments · program years 2019–2025
  1. EXCELSIUS GPS $35,093 30 payments
  2. MARS $12,274 8 payments
  3. Velys $11,292 4 payments
  4. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $9,083 19 payments
  5. ELSA $7,875 2 payments
  6. ExcelsiusGPS Robotic Navigation System $7,532 5 payments
  7. XLIF $7,307 37 payments
  8. Anthem $3,150 1 payment
  9. Trigger-Flex $3,000 1 payment
  10. Other - Miscellaneous $2,463 9 payments
  11. Other $22,262 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

457

Median for Neurosurgery: 83

Drug cost

$5,588

Median for Neurosurgery: $872

Branded share of claims

5.5%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 41 $1,416
Oxycodone Hcl Generic 124 $1,138
Gabapentin Generic 55 $901
Mupirocin Generic 113 $713
Hydromorphone Hcl Generic 27 $480
Cyclobenzaprine Hcl Generic 57 $386
Methocarbamol Generic 15 $259
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $150
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 12 $146

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$208,954

Medicare's payments for the services billed

Medicare patients

173

Average age 70

Services billed

658

88 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Depression 36%
Ischemic heart disease 35%
Chronic kidney disease 26%
COPD 24%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record